Literature DB >> 3532694

Reversibility of cerebral symptoms in severe hypertension in relation to acute antihypertensive therapy. Danish Multicenter Study.

A R Krogsgaard, A McNair, T Hilden, P E Nielsen.   

Abstract

Cerebral symptoms were registered in a multicenter study including 64 patients with severe hypertension, diastolic blood pressure (DBP) greater than or equal to 135 mmHg, and more or less pronounced hypertensive encephalopathy. The symptoms were: headache (70%), dizziness (35%), consciousness disturbances (28%), nausea (27%), paresis (23%), blurred vision (22%), paraesthesia (21%) and vomiting (14%). None had convulsions or coma. Initial treatment was furosemide i.v., and if DBP was greater than or equal to 125 mmHg after one hour, patients were randomized to treatment with either i.v. diazoxide (bolus injections of 75-150 mg) or i.m. dihydralazine (bolus injections of 6-12.5 mg). A gradual fall in blood pressure (BP) was obtained in all three groups. Along with BP reduction a substantial regression of neurological symptoms was registered. After 5 hours only minor cerebral symptoms were present without significant difference between diazoxide and dihydralazine. None developed cerebral complications. The study failed to show a significant correlation between BP reduction and regression of neurological symptoms graded semiquantitatively. Reduction of BP by titration using small repeated bolus injections is recommended, but oral treatment should be considered in the patients who are able to ingest peroral medication in spite of neurological symptoms.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3532694     DOI: 10.1111/j.0954-6820.1986.tb02726.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  2 in total

Review 1.  Pharmacological interventions for hypertensive emergencies.

Authors:  M I Perez; V M Musini
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

2.  A case of hypertensive encephalopathy with prominent brainstem presentation.

Authors:  E Medici; S Arabi; M Sebastianelli; O Pirani; E Giaccaglini
Journal:  Neurol Sci       Date:  2009-02-06       Impact factor: 3.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.